Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANT NSCLC Vaccine
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous, Subcutaneous, Oral, Intramuscular
01
Overview
**NANT NSCLC Vaccine** was an investigational, multi-agent combination-immunotherapy protocol for non-small cell lung cancer that had progressed after PD-1 or PD-L1 inhibitor treatment. The QUILT-3.044 Phase 1b/2 study combined metronomic chemotherapy and stereotactic radiation with checkpoint inhibitors, anti-VEGF therapy, tumor-antigen vaccines, the IL-15 superagonist ALT-803, and haNK natural-killer cells. Vaccine constituents included adenoviral vectors directed against CEA, HER2, MUC1, and brachyury and yeast-based vaccines directed against mutant RAS, CEA, and brachyury. The registered trial was withdrawn and enrolled zero participants. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT03169738/))
- Other names
- NANT Non-small Cell Lung Cancer VaccineQUILT-3.044QUILT3.044QUILT 3.044
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on NANT NSCLC Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANT NSCLC Vaccine.